Xellar Biosystems
Overview
Xellar Biosystems is an AI-driven biotechnology company specializing in drug discovery and development using advanced organ-on-a-chip technology and artificial intelligence. Founded in 2021, the company is headquartered in Cambridge, Massachusetts, with an additional location in Beijing, China. The company was co-founded by Xin Xie, who serves as the CEO. Xellar Biosystems has raised significant funding from investors including Legend Capital and TriApex Laboratories, reaching a total of $23.8 million in funding. The company integrates machine learning with large-scale wet-lab experiments to innovate in the drug discovery sector.
Recent Developments
- October 2024: Xellar Biosystems received CNY 100 million in funding (approximately $14 million USD) from multiple investors, including TriApex Laboratories and Zhengxuan Investment. This funding round was aimed at advancing their organ-on-chip platform and accelerating drug discovery research.
- July 2024: Xellar was highlighted among Greater China's top biotech deals, raising significant funds to expand their R&D capabilities.
- February 2024: Xellar joined the NVIDIA Inception program, which provides startups with access to cutting-edge research, technological support, and strategic industry partnerships.
- June 2024: The OC-Plex8/32, a microfluidic organ chip device from Xellar, was awarded the Q2 Product Award by Products That Count, emphasizing its advanced capabilities in 3D cell culture applications.
- August 2022: The company had previously raised $10 million in an angel round, supported by Yael Capital, Legend Capital, and ZhenFund.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | Cambridge, Massachusetts, USA |
| Founders | Xin Xie |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Legend Capital, TriApex Laboratories |
| Industry | Biotechnology |
| Number of Employees | Approximately 21 (as of recent estimates) |
Early History
Xellar Biosystems began its journey in 2021, founded in Boston by Xin Xie. The company aimed to address the traditional challenges in drug discovery by using a combination of AI-driven tools and organ-on-chip technology. In its early stage, Xellar focused on developing a sophisticated laboratory setting that replicates the complexities of human organs. This approach allowed the company to reduce reliance on animal testing and enhance the accuracy of drug testing. By 2022, the company successfully raised $10 million, attracting early support from notable investment firms which spurred its initial growth.
Company Profile and Achievements
Xellar Biosystems stands out in the biotechnology landscape by effectively combining organ-on-chip technology with artificial intelligence to create a holistic and interconnected model for drug development.
- 2023: Achieved participation in NVIDIA Inception, gaining valuable exposure to AI-enhanced research methodologies.
- Product Development: OC-Plex8/32 organ chip device received industry recognition for its innovation in microfluidic technology.
- Funding Milestones: Secured significant funding through angel rounds and follow-up investments, which have been instrumental in expanding their R&D capabilities.
- Technological Integration: The company has emphasized robust machine learning applications to interpret complex biological data.
Current Operations and Market Position
Xellar Biosystems continues to innovate in drug discovery through its unique combination of AI and microfluidic organ-on-chip technology. The company's current operations focus heavily on developing and refining these technologies to provide predictive models for pharmaceutical and biotech companies. Positioned in the competitive landscape of biotech firms leveraging AI for drug discovery, Xellar maintains a strong market position due to its cutting-edge technology and strategic partnerships with giants like NVIDIA.
Xellar Biosystems Owner
While Xellar Biosystems is a private entity co-founded by Xin Xie, it operates with significant financial backing from prominent investors that influence its strategic decisions. The company's ownership largely remains with its founders and key investors.
Xellar Biosystems Funding
The company has successfully completed several funding rounds, the latest being an angel+ round of CNY 100 million, backing from investors like Legend Capital and TriApex Laboratories, which has enabled it to broaden its research scope and accelerate product development.
Xellar Biosystems LinkedIn
Xellar Biosystems uses its LinkedIn platform to engage with the biotech community and stakeholders. It frequently shares updates about its technological advancements and strategic partnerships, acting as a vital tool for recruitment and investor relations.
Conclusion
Xellar Biosystems has rapidly established itself as a key player in the AI-driven drug discovery sector. By harnessing the power of AI and organ-on-chip technologies, it offers innovative solutions that address the complexities of human biology in drug research. Looking forward, Xellar is poised to deepen its impact in the biotechnology industry, with continued investment in research capabilities and strategic partnerships.